Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development is currently focused on three disease targets: Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH)/PBC and Respiratory Syncytial Virus (RSV).

Employee Rating

4.5More
TypePublic
HQWatertown, US
Founded1998
Size (employees)89 (est)
Websiteenanta.com
Enanta Pharmaceuticals was founded in 1998 and is headquartered in Watertown, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Enanta Pharmaceuticals

Jay R. Luly

Jay R. Luly

President, Chief Executive Officer and Director
Yat Sun Or

Yat Sun Or

Senior Vice President, Research & Development and Chief Scientific Officer
Paul J. Mellett

Paul J. Mellett

Senior Vice President, Finance & Administration and Chief Financial Officer
Show more

Enanta Pharmaceuticals Office Locations

Enanta Pharmaceuticals has an office in Watertown
Watertown, US (HQ)
500 Arsenal Street
Show all (1)
Report incorrect company information

Enanta Pharmaceuticals Financials and Metrics

Enanta Pharmaceuticals Revenue

Enanta Pharmaceuticals's revenue was reported to be $206.63 m in FY, 2018
USD

Revenue (FY, 2018)

206.6m

Net income (FY, 2018)

72.0m

EBIT (FY, 2018)

88.3m

Market capitalization (14-Dec-2018)

1.4b

Closing stock price (14-Dec-2018)

73.8

Cash (30-Sep-2018)

63.9m
Enanta Pharmaceuticals's current market capitalization is $1.4 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

32.1m47.7m160.9m88.3m102.8m206.6m

Revenue growth, %

49%237%(45%)

General and administrative expense

6.2m10.0m13.5m17.0m20.7m23.4m

R&D expense

16.8m18.7m23.2m40.5m57.5m94.9m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

893.0k2.2m42.1m77.5m57.4m11.6m48.4m13.0m14.0m10.4m9.0m7.5m38.1m44.0m57.3m

General and administrative expense

2.1m2.6m2.6m2.8m3.4m3.6m3.8m4.4m4.3m4.9m5.5m5.2m5.8m5.7m6.1m

R&D expense

4.3m4.7m4.6m4.5m5.4m6.3m9.0m9.1m10.8m12.5m13.0m15.4m18.0m21.5m28.5m

Operating expense total

6.4m7.3m7.2m7.3m8.8m9.9m12.9m13.6m15.1m17.5m18.5m20.6m23.7m27.2m34.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

8.9m30.7m21.7m16.6m65.7m63.9m

Accounts Receivable

808.0k1.7m15.3m12.8m10.6m67.2m

Inventories

1.6m1.6m8.3m9.2m3.5m

Current Assets

104.7m108.0m170.6m232.2m237.8m380.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

4.4m18.1m26.4m34.1m25.8m19.8m46.2m56.4m24.8m20.6m19.2m22.3m68.1m66.9m42.5m

Accounts Receivable

279.0k998.0k399.0k76.6m7.1m11.7m17.9m13.0m14.0m10.4m9.0m7.5m23.1m44.0m57.3m

Current Assets

94.4m99.3m111.7m185.1m177.8m172.6m209.0m242.7m241.8m224.1m190.6m206.1m247.6m305.7m339.9m

PP&E

1.1m1.4m1.6m1.9m2.3m2.6m7.9m7.7m7.5m8.3m8.5m8.1m7.9m8.6m8.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

9.6m34.4m79.0m21.7m17.7m72.0m

Depreciation and Amortization

221.0k352.0k639.0k1.7m2.1m2.5m

Inventories

(307.0k)568.0k(6.7m)(964.0k)3.5m

Accounts Payable

115.0k399.0k(543.0k)1.5m633.0k1.3m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(5.4m)(10.6m)39.5m42.0m70.8m73.2m26.2m24.5m23.5m(5.0m)(10.4m)(18.8m)11.7m24.2m44.5m

Depreciation and Amortization

75.0k154.0k242.0k129.0k270.0k435.0k339.0k772.0k1.2m493.0k1.0m1.6m587.0k1.2m1.9m

Accounts Payable

(648.0k)316.0k(190.0k)(1.3m)488.0k(332.0k)149.0k1.2m677.0k(1.3m)688.0k2.7m(129.0k)565.0k1.4m

Cash From Operating Activities

(5.9m)(10.0m)25.1m(5.6m)93.3m79.0m30.0m40.0m37.9m3.1m143.0k(4.7m)4.4m(3.2m)879.0k
USDY, 2018

Revenue/Employee

2.3m

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Enanta Pharmaceuticals Company Life and Culture

Report incorrect company information

Enanta Pharmaceuticals Frequently Asked Questions

  • When was Enanta Pharmaceuticals founded?

    Enanta Pharmaceuticals was founded in 1998.

  • Who are Enanta Pharmaceuticals key executives?

    Enanta Pharmaceuticals's key executives are Jay R. Luly, Yat Sun Or and Paul J. Mellett.

  • How many employees does Enanta Pharmaceuticals have?

    Enanta Pharmaceuticals has 89 employees.

  • What is Enanta Pharmaceuticals revenue?

    Latest Enanta Pharmaceuticals annual revenue is $206.6 m.

  • What is Enanta Pharmaceuticals revenue per employee?

    Latest Enanta Pharmaceuticals revenue per employee is $2.3 m.

  • Who are Enanta Pharmaceuticals competitors?

    Competitors of Enanta Pharmaceuticals include Ab Initio Biotherapeutics, OncoTartis and Eternygen.

  • Where is Enanta Pharmaceuticals headquarters?

    Enanta Pharmaceuticals headquarters is located at 500 Arsenal Street, Watertown.

  • Where are Enanta Pharmaceuticals offices?

    Enanta Pharmaceuticals has an office in Watertown.

  • How many offices does Enanta Pharmaceuticals have?

    Enanta Pharmaceuticals has 1 office.